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Abstract
Background: Hepatitis C virus (HCV) is one of the major health concerns globally, with genotype 3a as the most
prevalent in Pakistan. Lack of efficient HCV genotype 3a small animal models as well as genomic replicons has
hampered the complete understanding of its life cycle, pathogenesis and therapeutic options. In this study we
aimed to develop a persistent HCV genotype 3a infectious cell culture model.
Methods: We inoculated Huh-7 cells with HCV genotype 3a serum. Cells and media supernatant were collected at
different time periods up to 40
th day post infection. Culture media supernatant was also collected to find out its
ability to infect naive Huh-7 cells.
Results: HCV replication was confirmed at both RNA and protein level through Real Time RCR and western blot
using HCV core as marker. In order to validate the persistence of our model for HCV genotype 3a replication we
inhibited the HCV replication through core specific siRNAs. The HCV RNA was detected intracellularly from the day
one post infection up till 40
th day, while HCV core protein was detected from the second day up to 40
th day
consistently. In culture media supernatant HCV RNA was also actively detected conferring its ability to infect the
naive Huh-7 cells. Furthermore, core specific siRNA showed significant inhibition at 24
th hour post transfection both
at RNA and protein level with progressive increase in the expression of core gene after 3
rd day. It clearly depicts
that the Huh-7 successfully retained the HCV replication after degradation of siRNA.
Conclusion: Finally, we report that our persistent infection cell culture model consistently replicate HCV genotype
3a for more than 1 month.
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Introduction
HCV is a causal agent of both acute and chronic hepati-
tis [1] and is one of the foremost health problems affect-
ing nearly 350 million people worldwide [2]. Almost
10% of the population is chronically infected with HCV
in Pakistan predominantly by genotype 3a followed by
1a [3-5]. About 40-60% of HCV infected patients lead to
chronic liver diseases including liver fibrosis, liver cir-
rhosis, and hepatocellular carcinoma (HCC) [6,7].
The complete understanding of HCV life cycle and
pathogenesis has been impeded due to the unavailability
of a competent in vitro culture system and appropriate
small animal model. Currently, the only well-established
immunocompetent animal model for HCV infection is
the chimpanzee. However, due to strong ethical con-
cerns, endangered status and high expenses; its wide
spread use in hepatitis research has been hampered. Till
date, tree shrew (Tupaia sp.) is the only small animal
model that has been successfully infected by HCV,
although only after severe immunosuppression [8].
Immunodeficient urokinase plasminogen activator (uPA)
transgenic mice have been used to transplant human
hepatocytes, followed by HCV infection [9]. Different
HCV transgenic mice have also been produced that
express different HCV genes leading to numerous histo-
logical changes in mice liver, including development of
HCC [10,11]. However, the process of developing small
animal model is highly complicated due to the fact that * Correspondence: sajihassan2004@yahoo.com
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liver cells and severe immunosuppression [12].
Different groups have put their efforts to establish cell
culture systems highly supportive to HCV replication
[13-17]. Although most of the systems permit HCV
infection, yet the major draw back is the lack of HCV
virions production. However, key progress towards HCV
culturing was achieved by the HCV subgenomic repli-
con development enabling vigorous replication of HCV
in culture. In 2005 Wakita et al. successfully cloned
HCV genotype 2a JFH1 and transfected it in Huh-7 cell
line leading to successful replication and virions produc-
tion [18], while Zhong et al. achieved a very robust and
efficient system for infectious virions in Huh-7 cell line
[19]. Yi et al. were able to achieve efficient HCV virions
production with HCV genotype 1a J77-S virus in Huh-7
cell line [20]. Despite of their effectiveness the Huh-7
derived HCV virions producing systems have several
draw backs like utilization of unusual and rare cloned
H C Vg e n o t y p e2 aJ F H 1[ 1 8 ]a n du s eo fc l o n e dH C V
genotype 1a H77-S having five non-natural adaptive
mutations [20].
Recently, different groups have studied HCV replica-
tion in serum infected liver cell lines and hepatocytes,
which mimic the naturally occurring HCV virions biol-
ogy and kinetics of HCV infection in humans [21-25].
Among them, Huh-7 cell line has been used as model
cell culture system to study the mechanisms of HCV
associated hepatocarcinogenesis, by using either transi-
ent transfection or generating stably transfected cell
lines and viral load analysis, as these cells are permissive
to HCV infection and replication [25,26].
The subgenomic replicons, small animal models, and
infection based cell culture systems are mostly available
for genotype 1 and 2; and there is lack of any system
particularly for genotype 3a. So, in the current study; we
aimed to develop a persistent in vitro infection based
cell culture model in Huh-7 cells line by infecting them
with serum of HCV genotype 3a, providing the cells the
environment most closely to the natural one. Further-
more, we evaluated persistent HCV genotype 3a replica-
tion in our infection model by silencing HCV genotype
3a replication with siRNA targeting highly conserved
core region.
Results
Development of persistent HCV genotype 3a huh-7
infectious model
Huh-7 cells were infected with HCV genotype 3a serum
of high titer (> 1 × 10
8 copies/μl). RNA was extracted
from cells at different days 1, 10, 20, 30 and 40 and
reverse transcribed. Detection of HCV RNA was done
through HCV genotype 3a core gene specific primers by
semi quantitative RT-PCR which showed continuous
expression of HCV core gene in serum infected cells at
least up to 40
th days post infection. GAPDH was used
as internal control (Figure 1).
Monitoring infection of huh-7 cells using culture medium
from infected cells by semi quantitative PCR
After incubation of Huh-7 cells with infectious medium
presumably containing exocytosed viral particles. The
infectious nature of the cells was confirmed by extracting
viral RNA from medium. Total RNA from the culture
media was extracted at different intervals of time 1, 10,
20, 30, and 40
th day post infection and was subjected to
semi quantitative RT-PCR with core specific primers.
Results showed that viral RNA was coming out of the
cells in to culture medium on the 10
th day post infection.
The expression of core gene in the media suggests that
the infected cells exocytose viral particles in the medium
that turn naïve cell into infected ones (Figure 2).
Western blot analysis of HCV core protein expression in
serum infected cells
The RT-PCR results were further validated by western
blot. The protein was extracted from serum infected
cells at different time intervals 1-5, 10, 20, 30, 40
th day
and was subjected to western blot analysis. Hybridiza-
tion with anti-core antibody clearly showed the continu-
ous expression of core protein in serum infected cells
except at Day 1, possibly due to the fact that there may
be lack of development of intermediate negative strand
of HCV genotype 3a. GAPDH was used as internal con-
trol (Figure 3A, B).
Effect of core specific siRNA Csi476 on expression of HCV
core gene in serum infected huh-7 cells
We transfected core specific siRNA named Csi476 (100
μM) in our persistent HCV infection model and
Figure 1 Expression of core gene at different time periods.
Expression of core gene was detected at different time periods
from 1 to 40 days, after infection of Huh-7 cells with HCV genotype
3a serum. Upper row shows continuous core gene expression up to
40
th day while the lower row shows GAPDH that was used as
internal control.
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ferent days (1-5). Results showed significant inhibition
of HCV RNA as compared to positive control at 24 h
post transfection. HCV replication gradually increased
on day 3 and 4 while on 5
th day no inhibitory effect of
siRNA was seen on serum infected Huh-7 cells. Signifi-
cant decrease in HCV core gene expression was
observed on day 1
st (92%, *p < 0.01) and on the day 2
nd
(88%, *p < 0.01) after transfection (Figure 4A). Western
blotting also showed inhibition of the protein expression
level of HCV core gene on 1
st and 2
nd day while
GAPDH was used as internal control (Figure 4B).
Statistical analysis
Statistical analysis was carried out using SPSS software
(version 16.0, SPSS Inc). All Data are presented as mean
± SD. Numerical data were analyzed using student’s t-
test. P value < 0.05 was considered statistically
significant.
Discussion
To study the pathogenesis and better development of
therapy against HCV there is need of a cell culture
based system which supports HCV replication. Pre-
viously we have used MDBK, HELA, HEK-293 T and
Huh-7 cell lines for viral inoculation experiments and
found that Huh-7 cell line supported the HCV replica-
tion the most [23]. Huh-7 derived cell lines, are most
widely used infectious cell culture system for liver asso-
ciated diseases and fundamental studies for the develop-
ment of antiviral agents against HCV [19,27,28]. Several
alternative strategies are being used to back up the viral
component in the different models. Subgenomic repli-
cons system is one of the most commonly used cell cul-
ture system to investigate HCV-RNA replication and
different steps of viral life cycle [29]. Despite of its effec-
tiveness it can not exactly mimics the actual HCV
Figure 3 Confirmation of HCV infection in Huh-7 cells.( A )T h e
expression level of HCV genotype 3a core protein in serum infected
Huh-7 cells through western blot analysis showed gradual increase
of HCV core protein from day 1st to day 5th. GAPDH was used as
internal control. (B) Continuous expression of HCV Core protein in
serum infected Huh-7 cells at different time intervals form 1
st to
40
th day.
Figure 4 Inhibitory effect of HCV-3a core gene specific siRNA
in Huh-7 infectious model. (A) Real time Real time PCR of core
gene expression level after siRNA (Csi476) transfection in HCV
genotype 3a serum infected Huh-7 cells at different days (D1 to D5).
Maximum inhibition (92%) was seen at Day 1 of post infection. Core
gene expression started to gradually increase till 5
th day. Huh-7 cells
infected with HCV genotype 3a serum (H + S3a) and scramble
siRNA (Sc) used as positive control. Three independent experiments
were performed having triplicate samples. Error bars indicate SD, *p
< 0.01 GAPDH was used as internal control. (B) Western blot of HCV
Core protein in HCV genotype 3a serum infected Huh-7 cells
transfected with Csi476 from day one (D1) 1 to day five (D5).
Maximum HCV core protein inhibition was seen on day 1 (D1) as
compared to Huh-7 cells infected with HCV genotype 3a serum (H
+ S3a) and scramble siRNA (Sc) that were used as positive control.
Huh-7 cells were used as negative control and GAPDH was used as
internal control.
Figure 2 HCV core gene expressions in media supernatant. HCV
core gene expressions in media supernatant; showed that HCV RNA
was detected on the 10
th day onward till 40
th day post infection.
HCV RNA was not detected from 1
st to 9
th day of post infection.
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medium. In spite of viral replication, the biologically
relevant infectious viral particles cannot be demon-
s t r a t e db ys u c ha p p r o a c h .B u c ke ta l .a n dM o l i n ae ta l .
has successfully infected human primary hepatocytes
with the serum of patients infected with HCV genotype
1, 2, 3 and 4 and found efficient HCV replication
[21,22].
In the present study, we used serum of HCV genotype
3a infected patient, the most prevalent genotype in Paki-
stan [3,4] to infect Huh-7 cell line. Recently, it is
demonstrated that both 5’ and 3’ untranslated regions of
the viral HCV RNA genome play a pivotal role in trans-
lation of viral proteins via interaction with cellular fac-
tors including eukaryotic initiation factor 3 eIF3 [30],
40S ribosomal subunit [31], poly pyrimidine tract bind-
ing protein (PTB) [32] and microRNA 122 [33]. Besides,
it has been shown that intra genetic viral interactions
such as NS4a/NS5a are required for key pathways in
HCV life cycle. The hypothesis of using HCV infected
serum in the present study was, it would have full
l e n g t hH C Vg e n o t y p e3 aR N Ag e n o m ee n s u r i n gt h e
presence of all the necessary ingredients involved in
viral replication and poly protein precursor to infect
Huh-7 cells in vitro. Our results showed the presence of
HCV RNA in serum infected cells from day 1 to 40 post
serum inoculation. The serum infected cells steadily
showed the expression of viral core gene (Figure 1). In
the media HCV RNA was not detected till 10
th day due
to fact Huh-7 cells were not shedding viral particles in
to culture medium (Figure 2). This may be due to lack
of active exocytosis of viral particles showing absence of
replication intermediate [21]. It is interesting to find
that Huh-7 showed continuous expression of core pro-
tein from 2
nd day of infection to 40
th day suggesting
that replication of HCV is going on in serum infected
Huh-7 cells (Figure 3A, B). This finding is in accordance
with the earlier work done by El-Awady and his cowor-
kers, who reported HCV genotype 4a serum infection in
HepG2 cell line and found that viral proteins started to
express themselves 1 week post infection [21]. We pre-
sume that our in vitro system is highly likely to mimic
the in vivo HCV replication. Our work is in agreement
with the earlier reports of infection experiments
[19,23,24].
Furthermore, in this study we evaluated siRNA based
HCV genome silencing in our persistent HCV infection
Huh-7 cell model that efficiently supported HCV replica-
tion up to 40 days. In order to confirm that the HCV is
self replicating or due to HCV carry over, we subjected
our persistent HCV infection model in Huh-7 cells (post
40 days) to HCV RNA silencing through our previously
reported core gene specific siRNA [34]. Excitingly we
found significant HCV genotype 3a replication inhibition
(P-value = 0.00) nearly up to 92% after 24 h (Day 1) post
transfection but HCV titer started to increase after 48 h
(Day 2) onward and showed continuous replication from
72th hours (Day 3) (Figure 4A), whereas the control
siRNA (scramble) did not show any effect on inhibition
of HCV replication. HCV replication in the Huh-7 cells
was observed through semi quantitative RT-PCR by
u s i n gc o r es p e c i f i cp r i m e r s . Western blot results also
showed significant down regulation of core protein at day
one of post transfection (Figure 4B). These results vali-
date our previous study in which we found significant
inhibition in transiently infected Huh-7 cells. Our data is
in disagreement with Zekri et al. [26] who demonstrated
that siRNAs against 5’UTR of HCV genotype-4 inhibited
HCV replication in serum infected Huh-7 cells up to 7
days. Our results clearly depict that the most epic inhibi-
tory effect of siRNA was seen 24 h post transfection. The
difference may be due to the selection of two different
HCV regions and genotype.
Conclusions
We report that our infectious cell culture model in
Huh-7 cell line persistently support HCV genotype 3a
replication in vitro. The continuous expression of HCV
proteins and capacity of culture medium to transmit the
virus to naïve cells depicts this model as an efficient one
to evaluate HCV therapeutic options and molecular
studies.
Materials and methods
Serum sample collection
T h el o c a lH C Vg e n o t y p e3 ap a t i e n t ’ss e r u ms a m p l e s
were obtained from the CAMB diagnostic laboratory,
Lahore, Pakistan. Serum samples were stored at -70°C
prior to RNA extraction. For viral inoculation experi-
ments, 1 × 10
8 IU/ml viral load of genotype 3a was
used. HCV genotypes were determined by CAMB diag-
nostic laboratory, Lahore, Pakistan. The study was
approved by institutional ethics committee and Patient’s
written consent was obtained.
Cell culturing
Huh-7 cell line was maintained in Dulbecco’s modified
eagle medium (DMEM) supplemented with 100 μg/ml
penicillin; streptomycin and 10% fetal bovine serum
referred as complete medium (Sigma Aldrich, USA) at
37°C with 5% CO2. The medium was renewed every 3
rd
day and passaged every 4-5 days. Viable cells were
counted using 0.5% trypan blue (Sigma Aldrich, USA).
For 6-well plates briefly 3 × 10
5cells/well were plated
a n dc u l t u r e di nc o m p l e t em e d i u mu n t i l6 0 - 8 0 %
confluent.
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For viral inoculation, we used similar protocols as estab-
lished by Khaliq and co-workers (2010) with slight mod-
ifications. High viral titer > 1 × 10
8 IU/ml from HCV
genotype 3a patients was used as principle inoculums in
these experiments. Briefly, 3 × 10
7 Huh-7 cells were
seeded in 60 mm culture plates, in DMEM (Sigma
Aldrich, USA) as described under cell culturing heading.
On semi-confluency, cells were washed twice with
serum-free medium, then inoculated with 500 μl( 1×
10
8 IU/well) of HCV genotype 3a serum and 500 μl
serum free media. After 3 h media was diluted such that
the serum concentration becomes 10%. Cells were main-
tained overnight at 37°C in 5% CO2.T h en e x td a y ,
adherent cells were washed three times with 1X PBS,
and the incubation was continued in CCM.
siRNA transfection
siRNA used in this study named Csi476 was raised
against highly conserved C terminal sequence of HCV
core gene. Csi476 antisense AAGACGGGA-
TAAATTTCGCAACCTGTCTC and Csi476 sense
AATTGCGAAATTTATCCCGTCCCTGTCTC. Scram-
ble siRNA used in this study was termed sc and its
sequence was antisense AACCTGCATACGCGACTC-
GACCCTGTCTC and sense strand
AAGTCGAGTCGCGTATGCAGGCCTGTCTC.
To analyze the effect of siRNA on HCV infection,
s e r u mi n f e c t e dH u h - 7c e l l swere seeded in 6-well (3 ×
10
5/well) plates and cultured in CCM until they became
60-80% confluent. Transfection was performed with 100
μM/well core specific siRNA Csi476 or scrambled
siRNA in serum free media using Lipofectamine™ 2000
(Invitrogen) according to the manufacturer’s protocol.
Total RNA isolation
Total RNA was extracted from the media, HCV infected
Huh-7 cells or siRNA transfected HCV infected Huh-7
cells at different time periods using the Pure script
®
RNA Isolation kit (Gentra, USA) according to manufac-
turer protocol. RNA samples were stored at -70 to -80°
C until use or otherwise proceeded toward cDNA
synthesis.
Detection of HCV RNA through semi quantitative RT-PCR
Total RNA (1 μg) extracted was subjected to reverse
transcription with the help of oligo dT primer. Then the
cDNA was subjected to PCR with the Core gene specific
primers (Forward CCGTTGGCATGAAGTGTATG and
Reverse CCAGTGAAGAGAGCCTGACC).G A P D H
was used as internal control (Forward Primer ACCA-
CAGTCCATGCCATCA and Reverse Primer TCCAC-
CACCCTGTTGCTGTA). The PCR products were
subjected to electrophoresis to find out the desired
bands of HCV Core gene or GAPDH.
Quantification of core gene expression using real time
PCR
The effect of siRNA on HCV replication was analyzed
by expression analysis of HCV Core gene using specific-
primers of HCV Core on ABI 7500 Real Time PCR
using SYBR Green mix (Fermentas) according to manu-
facturer’s instructions. Template cDNA 0.5 μgw a su s e d
for the quantification of expression. GAPDH gene was
used as an internal control for normalization. The rela-
tive gene expression analysis was done by using SDS 3.1
software provided by ABI. Each Real Time PCR assay
was performed in triplicate. Level of Significance and
standard error were determined by SPSS software for
Windows.
Western blotting
To determine the protein expression levels of HCV
Core, in serum infected, and siRNA transfected (with
and without HCV genotype 3a Core siRNA Csi476 and
scramble siRNA) and non-transfected cells were lysed
with ProteoJET mammalian cell lysis reagent (Fermen-
tas, Canada). Equal amounts of total protein were sub-
jected to electrophoresis on 12% SDS-PAGE and
electrophoreticallty transferred to a nitrocellulose mem-
brane following the manufacturer’s protocol (Bio-Rad,
CA). After blocking non-specific binding sites with 5%
skimmed milk, blots were incubated with primary
monoclonal antibodies specific to HCV Core and
GAPDH (Santa Cruz Biotechnology Inc, USA) and sec-
ondary Horseradish peroxidase-conjugated anti-goat
anti-mouse antibody (Sigma Aldrich, USA). The protein
expressions were evaluated using chemiluminescence’s
detection kit (Sigma Aldrich, USA).
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